Patents Assigned to The Wellcome Trust
-
Patent number: 10987415Abstract: The present invention relates to a novel process of production of purified recombinant cholera toxin B (rCTB) which provides protection against diarrhea caused by various bacteria such as Vibrio cholerae and Enterotoxigenic Escherichia coli (ETEC). More particularly, the present invention relates to a process of production of rCTB with significantly higher yield and higher purity. The present invention also relates to a vaccine formulation having synergistic protection against Vibrio cholerae and cross protection against ETEC.Type: GrantFiled: December 9, 2016Date of Patent: April 27, 2021Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Tarun Sharma, Neeraj Joshi, Vibhu Kanchan, Deepa Sikriwal, Nidhi Shukla, Davinder Gill
-
Patent number: 10556000Abstract: The present invention relates to an improved thermostable spray dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses thermostable liquid, powder or granule-based rotavirus vaccine prepared using the spray drying process, such that the said vaccine has improved heat-stability, ease-of-use, ease-of-transportation and affordability features with significantly better chance of being adopted in developing and low income country's vaccination program.Type: GrantFiled: July 17, 2015Date of Patent: February 11, 2020Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Davinder Gill, Nitin Saigal, Sachin Kale, Tarun Sharma, Nidhi Shukla, Deepa Sikriwal, Robert Evans
-
Patent number: 10532093Abstract: The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that the said vaccine formulation possess improved heat-stability, easy to use and transport and highly affordable thereby meeting the requirements of developing and low income country's vaccination program. The said freeze dried rotavirus vaccine formulation along with reconstitution buffer is so engineered to be suitable for filling in appropriate packaging containers/ closures so designed such that they reduce the logistics requirement for storage.Type: GrantFiled: July 16, 2015Date of Patent: January 14, 2020Assignee: MDS WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Davinder Gill, Madhu Madan, Sachin Kale, Tarun Sharma, Nidhi Shukla, Deepa Sikriwal, Robert Evans
-
Patent number: 10183962Abstract: The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.Type: GrantFiled: February 24, 2015Date of Patent: January 22, 2019Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Davinder Gill, Kishore Harale, Manoj Kumar Chhikara
-
Patent number: 10105438Abstract: The present invention relates to an improved process of conjugation to obtain synthetic oligosaccharide-protein (OS-PR) conjugates. The process of synthetic OS-PR conjugation is a rapid process providing oligosaccharide-protein conjugates which are highly immunogenic and elicit specific and homogenous immune responses. The synthetic oligosaccharide comprising of four to eight repeating units of respective monomers and at least one in-built terminal amino linker, said synthetic polysaccharide mimics natural polysaccharide obtained from gram negative bacteria such as Neisseria meningitidis serogroups A, C, Y, W, X and Haemophilus influenzae and carrier protein is obtained from gram positive bacteria such as Clostridium tetani (tetanus toxoid) or Corynebacterium diphtheriae (CRM197) or their recombinant versions. The conjugation chemistry of the said oligosaccharide-protein conjugate of the present invention is thio-ether linkage. The present invention takes complete process time in the range of 14-22 hours.Type: GrantFiled: October 8, 2015Date of Patent: October 23, 2018Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Davinder Gill, Manoj Kumar Chhikara, Rakesh Rana, Juned Dalal, Deepti Singh
-
Patent number: 10011662Abstract: The present invention relates to a novel process for purifying bacterial polysaccharide. It is an efficient and scalable process for removing impurities from Neisseria meningitidis serogroup C (Men-C) polysaccharide which is capable of being used as such in a derivatized form or linked to other molecules, for the preparation of vaccines, more particularly conjugate vaccines for N. meningitidis infection.Type: GrantFiled: February 24, 2015Date of Patent: July 3, 2018Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Davinder Gill, Manoj Kumar Chhikara, Sandeep Sharma, Sarmad Hanif, Neeraj Joshi
-
Patent number: 9511133Abstract: A vaccine against cholera and/or ETEC is provided, comprising a Vibrio cholerae O1 cell, characterized in that said cell comprises O1 antigens of both Ogawa and lnaba serotypes. Genetically modified Vibrio cholerae O1 cells for use in such vaccines, DNA-constructs for the modification, uses for the vaccine and methods of making a vaccine are also provided.Type: GrantFiled: September 16, 2010Date of Patent: December 6, 2016Assignee: MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.Inventors: Jan Holmgren, Michael Lebens
-
Patent number: 8580497Abstract: The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumors of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics.Type: GrantFiled: December 2, 2010Date of Patent: November 12, 2013Assignee: The Wellcome TrustInventors: Mike Stratton, Andy Futreal, Richard Wooster, Richard Malcolm Marais, Chris Marshall
-
Patent number: 7947819Abstract: The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumors of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics.Type: GrantFiled: June 21, 2004Date of Patent: May 24, 2011Assignee: The Wellcome TrustInventors: Mike Stratton, Andy Futreal, Richard Wooster, Richard Malcolm Marais, Chris Marshall
-
Patent number: 7737152Abstract: The present invention pertains to certain 6-carboaryloxy-pyrazin-2-yl-carboaryl-amines of the following formula, and pharmaceutically acceptable salts thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., wherein Q is independently —N?; RP3 is independently a group of the formula -J1-L1-Z; -J1L1-Z is independently —NH—Z; Z is independently C6-14carboaryl and is independently unsubstituted or substituted; RP2 is independently —H; RP5 is independently a group of the formula —W—Y; W is independently —O—; Y is independently C6-14 carboaryl and is independently unsubstituted or substituted; and RP6 is independently —H. The present invention also pertains to pharmaceutical compositions comprising such compounds.Type: GrantFiled: December 22, 2005Date of Patent: June 15, 2010Assignee: The Wellcome Trust LimitedInventors: Caroline Joy Springer, Ion Niculescu-Duvaz, Esteban Roman Vela, Adrian Liam Gill, Richard David Taylor, Richard Malcolm Marais
-
Publication number: 20080015191Abstract: The present invention pertains to certain pyrazines and pyridines, and derivatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc.Type: ApplicationFiled: December 22, 2005Publication date: January 17, 2008Applicant: THE WELLCOME TRUST LIMITEDInventors: Caroline Springer, Ion Niculescu-Duvaz, Esteban Vela, Adrian Gill, Richard Taylor, Richard Marais
-
Publication number: 20030181660Abstract: A novel receptor, “LDL-receptor-related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.Type: ApplicationFiled: December 31, 2002Publication date: September 25, 2003Applicant: The WellcomeTrust Limited as Trustee for the Wellcome TrustInventors: John A. Todd, John W. Hess, Charles T. Caskey, Roger D. Cox, David Gerhold, Holly Hammond, Patricia Hey, Yoshihiko Kawaguchi, Tony R. Merriman, Michael L. Metzker, Yusuke Nakagawa, Michael S. Phillips, Rebecca C.J. Twells
-
Patent number: 6555654Abstract: A novel receptor, “LDL-receptor related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.Type: GrantFiled: February 14, 2000Date of Patent: April 29, 2003Assignee: The Wellcome Trust Limited as Trustee for the Wellcome TrustInventors: John A. Todd, John W. Hess, Charles T. Caskey, Roger D Cox, David Gerhold, Holly Hammond, Patricia Hey, Yoshihiko Kawaguchi, Tony R. Merriman, Michael L. Metzker, Yusuke Nakagawa, Michael S. Phillips, Rebecca C. J. Twells
-
Patent number: 5869247Abstract: A natural resistance-associated macrophage protein and corresponding promoter and antibodies specific thereto are provided. The promoter region exhibits polymorphisms and is useful as a diagnostic agent.Type: GrantFiled: October 8, 1996Date of Patent: February 9, 1999Assignee: The Wellcome Trust Limited as Trustee to the Wellcome TrustInventors: Charles Howard Barton, Jacqueline Katie White, Jenefer Mary Blackwell